Form 4: Spero Therapeutics CEO Sath Shukla Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Sath Shukla, CEO and President of Spero Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting RSUs.
Summary
- Sath Shukla, the CEO and President of Spero Therapeutics, sold shares of the company's common stock on August 2nd and August 5th, 2024.
- The sales were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on August 1, 2023.
- On August 2nd, 14,800 shares were sold at a price of $1.32 per share.
- On August 5th, 17,641 shares were sold at a price of $1.31 per share.
- Following these transactions, Shukla directly owns 1,143,566 shares of Spero Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, not necessarily indicative of management's view on the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future actions.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 08/01/2023 | Date RSUs were granted to the Reporting Person |
| 08/02/2024 | Date of first reported transaction (sale of 14,800 shares) |
| 08/05/2024 | Date of second reported transaction (sale of 17,641 shares) |
| 08/06/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.